4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dichlorophenyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid | 540524-87-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dichlorophenyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid
• 英文别名: 4-[3-[1-Benzhydryl-5-chloro-2-[2-[(2,6-dichlorophenyl)sulfonylamino]ethyl]indol-3-yl]propyl]benzoic acid
• CAS: 540524-87-6
• 化学式: C₃₉H₃₃Cl₃N₂O₄S
• 分子量: 732.127
• InChiKey: NAVPQFUKCFHYAR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10.4
• 重原子数：
  49
• 可旋转键数：
  13
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  96.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl 4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dichlorophenyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoate 在 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 以71%的产率得到4-{3-[1-benzhydryl-5-chloro-2-(2-{[(2,6-dichlorophenyl)sulfonyl]amino}ethyl)-1H-indol-3-yl]propyl}benzoic acid
  参考文献：
  名称：

  Benzenesulfonamide indole inhibitors of cytosolic phospholipase A2α: Optimization of in vitro potency and rat pharmacokinetics for oral efficacy

  摘要：

  The synthesis and structure-activity relationship of a series of benzenesulfonamide indole inhibitors of cPLA(2)alpha are described. Substitution of the benzenesulfonamide led to analogues with 50-fold improvement in potency versus the unsubstituted benzenesulfonamide lead compound. Rat pharmacokinetics in a minimal formulation was used to prioritize compounds, leading to the discovery of a potent inhibitor of cPLA(2)alpha With oral efficacy in models of rat carrageenan paw edema and Ascaris suum airway challenge in naturally sensitized sheep. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2007.10.060

文献信息

• Inhibitors of cytosolic phospholipase A2
  申请人：Wyeth

  公开号：US20030144282A1

  公开（公告）日：2003-07-31

  This invention provides substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

  这项发明提供了一般式如下的取代吲哚化合物： 1 及其药用可接受的盐形式，以及将这些化合物用作各种磷脂酶酶的抑制剂的方法，特别是磷脂酶A 2 酶，并用于医疗治疗、预防和抑制疼痛和炎症。
• Methods for the use of inhibitors of cytosolic phospholipase A2 in the treatment of thrombosis
  申请人：Clerin Valerie

  公开号：US20080009485A1

  公开（公告）日：2008-01-10

  This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds in the treating or preventing thrombosis in a mammal, or preventing progression of symptoms of thrombosis.

  这项发明提供了一种使用通式所示的取代吲哚化合物及其药用盐形式的方法。该发明提供了一种在哺乳动物中治疗或预防血栓形成，或预防血栓形成症状进展的化合物使用方法。
• Methods for treating arthritic disorders
  申请人：Wyeth

  公开号：US20030166649A1

  公开（公告）日：2003-09-04

  This invention provides methods for treating in mammals arthritic or rheumatic disorders using substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

  本发明提供了一种使用一般式（1）的取代吲哚化合物及其药学上可接受的盐形式来治疗哺乳动物的关节炎或风湿性疾病的方法，以及使用这些化合物作为各种磷脂酶酶活性抑制剂，特别是磷脂酶A2酶的抑制剂的方法，并用于医疗治疗、预防和抑制疼痛和炎症。
• Methods for the use of inhibitors of cytosolic phospholipase A2
  申请人：McKew C. John

  公开号：US20060014759A1

  公开（公告）日：2006-01-19

  This invention provides methods for the use of substituted indole compounds of the general formula: and pharmaceutically acceptable salt forms thereof. The invention provides methods for the use of the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition diseases and disorders including asthma, stroke, atherosclerosis, multiple sclerosis, Parkinson's disease, arthritic disorders, rheumatic disorders, central nervous system damage resulting from stroke, central nervous system damage resulting from ischemia, central nervous system damage resulting from trauma, inflammation caused or potentiated by prostaglandins, inflammation caused or potentiated by leukotrienes, inflammation caused or potentiated by platelet activation factor, pain caused or potentiated by prostaglandins, pain caused or potentiated by leukotrienes, and pain caused or potentiated by platelet activation factor.

  这项发明提供了使用一般式为的取代吲哚化合物及其药学上可接受的盐形式的方法。该发明提供了将该化合物用作各种磷脂酶酶活性抑制剂的方法，特别是磷脂酶A2酶，并用于医疗治疗、预防和抑制哮喘、中风、动脉粥样硬化、多发性硬化症、帕金森病、关节炎性疾病、风湿性疾病、中风引起的中枢神经系统损伤、缺血引起的中枢神经系统损伤、创伤引起的中枢神经系统损伤、由前列腺素引起或增强的炎症、由白三烯引起或增强的炎症、由血小板活化因子引起或增强的炎症、由前列腺素引起或增强的疼痛、由白三烯引起或增强的疼痛和由血小板活化因子引起或增强的疼痛的疾病和疾患的方法。
• Methods for treating asthmatic conditions
  申请人：Wyeth

  公开号：US20030149029A1

  公开（公告）日：2003-08-07

  This invention provides methods for treating in mammals asthma and asthmatic conditions using substituted indole compounds of the general formula: 1 and pharmaceutically acceptable salt forms thereof, and methods for using the compounds as inhibitors of the activity of various phospholipase enzymes, particularly phospholipase A 2 enzymes, and for the medical treatment, prevention and inhibition of pain and inflammation.

  本发明提供了一种使用通式为1的取代吲哚化合物及其药学上可接受的盐形式，治疗哮喘和哮喘症状的哺乳动物的方法，并且提供了使用这些化合物作为各种磷脂酶酶活性抑制剂的方法，特别是磷脂酶A2酶的方法，以及用于医疗治疗、预防和抑制疼痛和炎症的方法。